Why Sangamo Therapeutics (SGMO) Is Down 21.1% After Steep Q3 Revenue Drop and Nasdaq Compliance Extension [Yahoo! Finance]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Yahoo! Finance
net loss of US$34.93 million, while also disclosing new advancements in its clinical pipeline and ongoing efforts to secure business partnerships and regulatory clarity for its Fabry disease program. An important insight is that Sangamo received a 180-day extension from Nasdaq to regain minimum bid price compliance, highlighting heightened pressures related to its financial stability and continued listing status amid ongoing clinical developments. We'll take a look at how Sangamo's steep revenue decline and Nasdaq extension impact the company's investment narrative and outlook. Find companies with promising cash flow potential yet trading below their fair value Sangamo Therapeutics Investment Narrative Recap For investors in Sangamo Therapeutics, the core belief hinges on the company's ability to translate promising clinical progress, particularly in Fabry disease, into regulatory approvals, partnerships, and ultimately sustained revenue. The recent steep revenue drop and Na
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathyGlobeNewswire
- How Recent Developments Are Rewriting the Story for Sangamo Therapeutics [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry DiseaseGlobeNewswire
- Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SGMO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
SGMO
Earnings
- 11/6/25 - Miss
SGMO
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- SGMO's page on the SEC website